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Background: Although immunotherapy has emerged as the “next generation” of cancer
treatments, it has not yet been shown to be successful in the treatment of patients
with prostate cancer, for whom therapeutic options remain limited to radiotherapy and
androgen (hormone) deprivation therapy. Previous studies have shown that priming
natural killer (NK) cells isolated from healthy individuals via co-incubation with CTV-1 cells
derived from an acute lymphoblastic leukemia (ALL) enhances their cytotoxicity against
human DU145 (metastatic) prostate cancer cells, but it remains unknown to what extent
NK cells from patients with prostate cancer can be triggered to kill. Herein, we explore the
phenotype of peripheral blood NK cells in patients with prostate cancer and compare the
capacity of CTV-1 cell-mediated priming and IL-2 stimulation to trigger NK cell-mediated
killing of the human PC3 (metastatic) prostate cancer cell line.
Methods: The phenotype of resting, primed (co-incubation with CTV-1 cells for 17 h) and
IL-2 activated (100 IU/ml IL-2 for 17 h) NK cells isolated from frozen-thawed peripheral
blood mononuclear cell (PBMC) preparations from patients with benign disease (n = 6)
and prostate cancer (n = 18) and their cytotoxicity against PC3 and K562 cells was
determined by flow cytometry. Relationship(s) between NK cell phenotypic features and
cytotoxic potential were interrogated using Spearman Rank correlation matrices.
Results and Conclusions: NK cell priming and IL-2 activation of patient-derived NK
cells resulted in similar levels of cytotoxicity, but distinct NK cell phenotypes. Importantly,
the capacity of priming and IL-2 stimulation to trigger cytotoxicity was patient-dependent
and mutually exclusive, in that NK cells from ∼50% of patients preferentially responded
to priming whereas NK cells from the remaining patients preferentially responded to
cytokine stimulation. In addition to providing more insight into the biology of primed
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and cytokine-stimulated NK cells, this study supports the use of autologous NK cell-
based immunotherapies for the treatment of prostate cancer. However, our findings also
indicate that patients will need to be stratified according to their potential responsiveness
to individual therapeutic approaches.
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INTRODUCTION
The 2012 GLOBOCAN project revealed prostate cancer to be the
4th most common cancer in the world, with 1.1 million cases
reported. Prostate cancer typically occurs in men over the age
of 50 yrs and is the most common male cancer in the developed
world (1). In 2014, there were 45,406 new cases of prostate cancer
reported and 12,082 deaths from the disease (33 per day) in the
UK (2).
Patients with confirmed prostate cancer are stratified
according to the D’Amico risk classification (i.e., low,
intermediate, and high risk) which predicts the likelihood
of a patient suffering biochemical recurrence following treatment
(3, 4). Stratification is based on the patient’s clinical tumor, node
and stage of metastasis (TNM), serum prostate specific antigen
(PSA) levels, and biopsy Gleason score (3, 4). Due to the slow
growing nature of prostate cancer, patients with low risk disease
are typically assigned to active surveillance, as the disease is
unlikely to progress within their life time. In contrast, patients
at intermediate and high risk, and young patients at low risk
undergo active treatment as disease progression is more likely in
these individuals (5).
The primary treatment for advanced metastatic prostate
cancer is androgen (hormone) deprivation therapy (ADT), with
upfront chemotherapy if medically fit and with good renal
function. Although the majority of patients initially respond to
ADT, as evidenced by disease regression and disease stability (5),
it is inevitable that disease will progress and become hormone-
resistant. At this point, second-line hormone therapy followed
by further hormone manipulation therapy is considered, but will
typically deliver only a very limited effect.
Immunotherapy involving stimulating the patient’s own
immune system to retarget their cancer is emerging as the next
generation of cancer treatment (6). Currently, the only approved
immunotherapy for treating castration-resistant prostate cancer
is Sipuleucel-T immunotherapy which has been shown to
improve the median overall survival by 4.1 months compared
to a placebo group (7). Although preventing tumor-mediated
immunoregulation using immune checkpoint inhibitors such as
Ipilimumab has shown some success in treating immunogenic
cancers such as melanoma and non-small cell lung cancer,
their use in patients with prostate cancer has not been shown
to improve overall survival (8). However, some evidence of
beneficial effects have been observed and clinical trials testing
Ipilimumab in combination with other standard prostate cancer
treatments (e.g., ADT) are ongoing (9).
Natural killer (NK) cells were first identified on the
basis of their natural cytotoxicity toward cancerous cells and
a number of NK cell-based immunotherapies are now in
development (10–15). As reviewed by Sabry and Lowdell
(16), the cytotoxic function of NK cells is controlled by the
balance of signals transduced via activating and inhibitory
receptors following ligation with stress ligands and MHC
class I molecules, respectively (Dynamic Equilibrium Theory).
Bryceson et al. demonstrated that natural cytotoxicity requires
the co-engagement of multiple activating receptors (17, 18).
Furthermore, work by Lowdell et al. led to the hypothesis that the
natural cytotoxicity mechanism can be divided into two discrete
stages; “priming” and “triggering” (16, 19, 20). For this, they
hypothesized that the “priming” signal can be delivered either
by the ligation of the appropriate number and combination of
activating receptors with their target ligands or via an activating
cytokine (e.g., IL-2). The “triggering” signal requires the ligation
of at least one additional activating receptor to its target ligand
that is specific to stressed cells (16).
Tumor primed NK cells (TpNK) can be generated in vitro
by co-incubating resting NK cells with the acute lymphoblastic
leukemia (ALL) cell line CTV-1 (19). Phenotypically, tumor
primed NK cells appear distinct from resting NK cells in that they
exhibit reduced expression of activating receptors (e.g., CD16,
NKG2D, NKp46), both in terms of intensity and proportion,
whereas both the proportion and intensity of expression of
co-receptors (e.g., CD69 and CD25) are up-regulated (19, 20).
Priming NK cells from healthy volunteers in this way has been
reported to enhance their cytotoxicity against NK cell-resistant
tumor cell lines such as the humanmetastatic prostate cancer cell
line DU145 (20).
The therapeutic potential of an autologous NK cell-
based therapy requires that patient-derived NK cells can
be appropriately triggered. Herein, we determined whether
activation of NK cells isolated from thawed peripheral blood
mononuclear cell (PBMC) preparations derived from patients
with prostate cancer by either co-incubation with mitomycin
C treated CTV-1 cells or stimulation with IL-2 enhanced their
capacity to kill the human metastatic disease-derived prostate
cancer cell line PC3.
Tumor priming and IL-2 stimulation of patient-derived NK
cells resulted in similar levels of cytotoxicity, but distinct NK
cell phenotypes. Importantly, the capacity of priming and IL-
2 stimulation to trigger cytotoxicity was patient-dependent and
mutually exclusive, in that NK cells from ∼50% of patients
preferentially responded to tumor priming, whereas NK cells
from the remaining patients preferentially responded to IL-
2 stimulation. In addition to providing more insight into
the biology of tumor primed and cytokine-stimulated NK
cells, this study supports the use of autologous NK cell-based
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immunotherapies for the treatment of prostate cancer. However,
our findings also indicate that patients will need to be
stratified according to their potential responsiveness to individual
therapeutic approaches.
METHODS
Patients and Ethical Approval
Ethical approval for the study cohort (Ethical Approval Number
14/ES/1014) was obtained from the East of Scotland Research
Ethics Service (EoSRES). Patients suspected of having prostate
cancer who attended the Urology Clinic at Leicester General
Hospital (Leicester UK) between 14th August 2014 and 3rd
December 2015 were given the opportunity to take part in
the study and provide a peripheral blood sample. Approval
for the collection of peripheral blood from healthy volunteers
was obtained from the Nottingham Trent University College of
Science and Technology Human Ethics Committee (Application
Number 435). Healthy volunteers and patients were given
information sheets detailing the nature of the study and those
wishing to take part were provided the opportunity to discuss
and ask questions. All participants provided informed consent
and were assigned a number to maintain anonymity. Participants
provided a 60mL peripheral blood sample which was obtained by
venepuncture. Of the 24 individuals who attended the Urology
Clinic at Leicester General Hospital and were included in the
study, 6 were diagnosed as having benign disease, and 18 patients
were diagnosed with prostate cancer, as determined by TRUS
biopsy. Gleason scores of the 18 cancer patients were; Gleason
6 (n = 3), Gleason 7 (n = 5), Gleason 9 (n = 8), and Gleason 10
(n= 2).
Cell Culture
The CTV-1 cell line was purchased from the Leibniz-Institut
DSMZ—Deutsche Sammlung von Mikroorganismen und
Zellkulturen GmbH (Braunschweig, Germany) and maintained
in RPMI 1640 (LONZA) supplemented with 10% v/v fetal bovine
serum (FBS) (Hyclone) and 1% v/v L-Glutamine (LONZA).
The PC3 cell line was purchased from ATCC and maintained in
Hams F-12K (Kaighn’s) medium (GIBCOTM) supplemented with
10% v/v FBS and passaged using 1X trypsin—versene (LONZA).
The K562 cell line was purchased from ATCC and maintained
in iscove’s modified dulbecco’s medium (IMDM) (LONZA)
supplemented with 10% v/v FBS.
Peripheral Blood Mononuclear (PBMC)
Isolation
Peripheral blood (60ml) was collected using standard procedures
and aliquoted (30ml) into two sterile 50ml polypropylene
FalconTM tubes containing 300 µl of heparin (1,000 IU/ml,
Sigma). Samples were immediately transferred to the John van
Geest Cancer Research Centre at Nottingham Trent University
(Nottingham, UK) and processed immediately upon receipt—all
samples were processed within 2 h. Blood was diluted 1 in 3 with
phosphate buffered saline (PBS, LONZA) and layered over Ficoll
Paque (GE Healthcare Life Sciences) in LeucoSep R© tubes (20ml
per tube). The tubes were subsequently centrifuged at 800 g for
20min. The PBMC layer was collected and washed twice with
PBS before being counted using trypan blue dye exclusion (Santa
Cruz Biotechnology). PBMCs were frozen down in 90% v/v FBS,
10% v/v Dimethyl sulfoxide (DMSO) at 106 cells per vial and
stored in liquid nitrogen.
NK Cell Isolation and Activation
PBMCswere defrosted, washed and rested for 30min in complete
medium (RPMI 1640 supplemented with 10% v/v FBS and 1% v/v
L-Glutamine). Natural killer (NK) cells were isolated bymagnetic
beads using the human NK cell negative selection isolation kit
(Miltenyi Biotec) according to the manufacturer’s instructions
and counted using trypan blue with the cells exhibiting a viability
of >98%. Flow cytometry analysis revealed that following
isolation, the purity of the NK cells averaged 82%. CTV-1 cells
were pelleted, counted by trypan blue exclusion, re-suspended
to a concentration of 7 × 106 viable cells/ml and then treated
with 33µg/ml Mitomycin C (Sigma) for 2 h at 37◦C, 5% v/v
CO2. Following treatment, the cells were washed three times with
PBS and then re-suspended in complete medium and recounted.
For each patient, NK cells were activated by (1) co-incubation
with mitomycin C treated CTV-1 cells at a 1:2 (NK:CTV-1) ratio
in complete medium or (2) incubation in complete medium
containing 100 IU/ml of IL-2 (PeproTech). As a control, resting
NK cells were incubated at a concentration of 2× 106 cells/ml in
complete medium for 17 h overnight.
Cytotoxicity Assay
The non-adherent K562 cells were pelleted at 400 g for 5min,
whereas the adherent PC3 cells were harvested using 1X Trypsin-
Versene and then pelleted at 300 g for 5min. Both cell lines were
counted using trypan blue dye exclusion (>95% viability) and
were used as target cells. Target cells were stained with 200 nM
MitoTrackerTM Green FM (ThermoFisher Scientific) in RPMI
1640 alone at a concentration of 2× 106 viable cells/ml for 20min
at 37◦C, 5% v/v CO2 in the dark. Following incubation, the target
cells were washed three times with PBS and then re-suspended
in IMDM (K562) or Hams F-12K (Kaighns) medium (PC3). The
cells were then recounted using trypan blue dye exclusion (>95%
viability) and diluted to a concentration of 1.0 × 106 viable
cells/ml.
NK cells activated overnight for 17 h were pelleted, re-
suspended in fresh complete RPMI medium, counted (NK cells
are smaller in size compared to CTV-1 cells) and diluted to a
concentration of 1.0 × 106 NK viable cells/ml. NK cells (150 µL,
150,000 cells) were co-incubated with target cells (30 µL PC3 or
K562, 30,000 cells) plus an additional 120 µL complete medium
in 12 × 75mm polycarbonate tubes for 3 h at 37◦C, 5% v/v CO2.
As a control, target cells were also analyzed alone for background
death. For this, 10µl of Propidium Iodide (50µM/ml) was added
to each tube prior to sample analysis. Samples were acquired on
a Beckman Coulter GalliosTM flow cytometer. For each tube a
minimum of 5,000 events were acquired and data analyzed using
the Beckman Coulter KaluzaTM v1.3 software.
Characterizing the NK Cell Phenotype
To measure the phenotype of both resting and activated NK
cell populations, 1.5 × 105 NK cells were added to 12 ×
75mm tubes and washed with Wash Buffer (PBS + 0.5% w/v
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TABLE 1 | Monoclonal antibody panel 1.
Antibody Fluorochrome Clone Supplier
CD2 FITC TS1/8 BioLegend
CD96 PE NK92.39 BioLegend
CD56 ECD N901 Beckman Coulter
CD16 PerCP-Cy5.5TM 3G8 BioLegend
CD137 PE-Cy7 4B4-1 BioLegend
CD69 APC FN50 BioLegend
CD3 Alexa FluorTM 700 UCHT1 BioLegend
CD19 Alexa FluorTM 700 HIB19 BioLegend
CD107a APC-Cy7TM H4A3 BioLegend
LIVE/DEADTM dye ThermoFisher scientific
TABLE 2 | Monoclonal antibody panel 2.
Antibody Fluorochrome Clone Supplier
DNAM-1 FITC 11A8 BioLegend
NKG2D PE 5C6 eBioscience
CD56 ECD N901 Beckman Coulter
CD16 PerCP-Cy5.5TM 3G8 BioLegend
NKp46 PE-Cy7TM 9E2 BioLegend
GITR APC ebioAITR BioLegend
CD3 Alexa FluorTM 700 Cr24.1 BioLegend
CD19 Alexa FluorTM 700 HIB19 BioLegend
OX40 APC-Cy7TM Ber-ACT35 BioLegend
LIVE/DEADTM Dye Violet ThermoFisher scientific
BSA, 0.02% w/v sodium azide). NK cells were incubated with
antibody panels (detailed in Tables 1, 2) for 15min in the
dark at room temperature. The cells were washed with PBS,
after which they were incubated with 1ml of LIVE/DEADTM
Fixable Violet solution (ThermoFisher Scientific) according to
the manufacturer’s instructions. Cells were washed with Wash
Buffer and re-suspended in IsotonTM II diluent Beckman Coulter.
Data were acquired on a Beckman Coulter GalliosTM flow
cytometer and analyzed using Beckman Coulter KaluzaTM v1.2
software.
Statistical Analysis
Graphs were created using GraphPad Prism v7. All datasets
were assessed for Gaussian distribution. Significant differences
in the expression of NK cell receptors between resting NK cells,
CTV-1 primed NK cells and IL-2 stimulated NK cells were
assessed by repeated measures two way ANOVA with a Tukey
multiple comparisons ad-hoc test. Correlations between receptor
expression and cytotoxic killing were assessed using two tailed
non-parametric Spearman Correlation tests.
RESULTS
Optimisation of the NK Cell Priming Assay
and Generation of Evidence to Suggest
That Down-Regulation of Activating
Receptors Does not Necessarily Indicate
NK Cell Dysfunction
It has previously been reported that NK cells from healthy
individuals can be primed by co-incubation with CTV-1 cells,
thereby enabling them to kill human DU145 prostate cancer
cells (20). During optimisation of our methods utilizing healthy
cells, NK cells were primed using different NK:CTV-1 ratios
(i.e., 2:1, 1:1, 1:2, and 1:4) and their cytotoxicity against PC3
cells (metastatic prostate cancer cell) assessed. As a reference,
the cytotoxic capacity of CTV-1 primed NK cells against K562
(chronic myelogenous leukemia) cells and resting NK cells
against both K562 and PC3 cell lines was also determined.
Resting NK cells from three healthy individuals killed 2.7,
10, and 8.8% of PC3 cells and 68.6, 83.7, and 43.8% of K562
cells, respectively (Figures 1A–C). Priming with CTV-1 cells
enhanced the cytotoxicity of NK cells from the healthy volunteers
against PC3 cells: For two healthy volunteers (1 and 3), PC3
lysis was maximal at the 1:2 ratio (lysed PC3 cells; 35.5 and
26.5%, respectively), whereas for the third (healthy volunteer
2) PC3 lysis was maximal at the 1:1 ratio (34% lysed cells)
(Figures 1A–C). In general, increasing the proportion of CTV-
1 cells within the priming ratio beyond that which induced a
peak level of cytotoxicity resulted in a reduced lysis of PC3 cells.
Interestingly, for the NK cells from healthy volunteers 1 and
2, priming with CTV-1 cells reduced their cytotoxicity against
K562 cells compared to their resting NK cell counterparts. The
reduction in K562 lysis increased further as the proportion of
CTV-1 cells in the priming ratio increased (Figures 1A,B). For
healthy volunteer 3, priming at the 2:1 ratio resulted in a 34.6%
increase in the killing of K562 cells, with further increases in
the proportion of CTV-1 in the priming ratio resulting in a
reduced lysis of K562 cells (Figure 1C). Analysis of the NK cell
phenotype before and after priming revealed that the reduction
in K562 lysis significantly correlated with a down-regulation in
the proportion of NK cells expressing the activating receptors
NKG2D (rs = 0.780, P = 0.0015) and NKp46 (rs = 0.643, P =
0.0153) (Figures 1D,E). For subsequent experiments, NK cells
were primed at the 1:2 NK:CTV-1 ratio.
Influence of CTV-1 Priming or IL-2
Activation on the Cytotoxicity of NK Cells
From Patients With Prostate Cancer
Against K562 and PC3 Cells
Next, we wished to assess the influence of CTV-1 priming and IL-
2 (100 U/ml) activation on the cytotoxicity of NK cells isolated
from thawed PBMC preparations derived from patients with
prostate cancer against PC3 and K562 cells. Sufficient NK cells to
perform both the priming and IL-2 stimulation assays were only
obtained from 21 of 24 patients (5 benign, 16 cancer). Sufficient
NK cells to test the priming assays, but not the IL-2 stimulation
assays were obtained from one of the individuals with benign
disease. Only the phenotype and function of resting NK cells was
possible for the remaining two patients with prostate cancer.
As shown in Figure 2A, resting NK cells from 7 of 22 patients
killed between 56 and 87% of K562 cells, whereas the NK cells
from the other 15 patients only killed between 4.8 and 23.1% of
K562 cells. Priming at a 1:2 NK:CTV-1 ratio for 17 h decreased
NK cell-mediated killing of K562 cells (median −40.7%, range
−11.4% to −58.8%) for 9 out of 22 patients, whereas a small
increase in killing of K562 cells was observed for the other 13
patients (median +7%, range +0.6% to +33.4%). Stimulation of
Frontiers in Immunology | www.frontiersin.org 4 January 2019 | Volume 9 | Article 3169
Hood et al. Triggering of Prostate Cancer Patient-Derived NK Cells
FIGURE 1 | Optimisation of the NK:CTV-1 priming ratio using NK cells from healthy volunteers. NK cells were isolated from thawed PBMCs that had previously been
generated from the peripheral blood of healthy individuals and co-incubated with mitomycin C treated CTV-1 cells at ratios 2:1, 1:1, 1:2, 1:4 for 17 h at 37◦C. NK cells
incubated in isolation were used as controls. The phenotype and cytotoxic function of the primed NK cells were then assessed by flow cytometry. For each priming
ratio, the ability of primed NK cells to lyse K562 cells and PC3 cells at a 5:1 effector to target ratio were measured. (A–C) Cytotoxicity against K562 and PC3 cells for
three healthy volunteers. (D,E) Significant correlation between K562 lysis and expression of activating receptors NKG2D and NKp46 on primed NK cells, respectively.
the NK cells with 100 IU of IL-2 over 17 h resulted in increased
killing of K562 cells (median +17.4%, range +6.4% to +46.9%)
for all but one individual, for whom killing decreased by 1.6%
(Figure 2B). IL-2 stimulation was more effective at enhancing
the NK cytotoxicity toward K562 cells, whereas priming often
resulted in a reduction in lysis (Figure 2C).
Although resting NK cells from the majority of patients
exhibited low cytotoxicity against PC3 cells (median 3.6%,
range 0% to 32.1%), cytotoxic potential was enhanced following
priming with CTV-1 (median 14.4%, range 6.2% to 44.2%)
(Figure 2D). This increased ability to kill PC3 cells was
comparable to that which was induced by IL-2 stimulation
(median 15.7%, range 2.8% to 61.9%) (Figure 2E). Due to the
large range of cytotoxic responses against PC3 cells that were
observed for activated NK cells (by either method), the patients
from whom these were isolated were divided into two groups;
(1) those that functionally responded better to NK cell priming
than IL-2 stimulation (10 out of 21 patients) and (2) those that
functionally responded better to IL-2 stimulation than NK cell
priming (11 out of 21 patients). As shown in Figure 2F, those
patients that responded better to NK cell priming exhibited a
median increase in killing of PC3 cells of +19% (range of +6%
to +36.5%) compared to a median increase of +5.3% (range
−3.9% to +19.1%) when NK cells were stimulated with IL-2.
For the patients that responded better to IL-2 stimulation, the
median increase in lysis of PC3 cells was +26.5% (range +8.4%
to +40.3%) compared to a median increase of +4.9% (range
−20.8% to+15.2%) when the NK cells were primed (Figure 2G).
Patients were then grouped according to whether priming
increased or decreased K562 lysis (Figure 2H). For each
group, the increase in cytotoxic response toward PC3 cells
against that achieved when the NK cells were stimulated
with IL-2 were compared (Figures 2I–K). NK cells from all
but one of the patients that exhibited a reduced cytotoxicity
against K562 cells after priming with CTV-1 cells (n = 9)
exhibited a better cytotoxic response to PC3 cells when
stimulated with IL-2 (Figures 2J,K). In contrast, NK cells
from 9 of 11 patients that exhibited an increased cytotoxicity
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FIGURE 2 | Influence of CTV-1 priming and IL-2 activation on the cytotoxicity of patient-derived NK cells against K562 and PC3 target cells. NK cells were isolated
from thawed PBMC samples derived from peripheral blood of patients with benign prostate disease and patients with prostate cancer. For each patient, the NK cells
were either primed with mitomycin C treated CTV-1 cells at a 1:2 ratio or activated with 100 IU IL-2, after which their ability to lyse K562 cells and PC3 cells at a 5:1
effector to target ratio was measured using flow cytometry. Comparison of cytotoxic responses toward K562 cells; (A) resting NK cells vs. primed NK cells, (B) resting
NK cells vs. IL-2 activated NK cells, (C) change in lysis of K562 cells effected by priming compared to IL-2 activation. Assessment of cytotoxic responses toward PC3
cells; (D) resting NK cells vs. primed NK cells (E) resting NK cells vs. IL-2 activated NK cells, (F) patient-derived NK cells that lysed more PC3 cells following priming
compared to following IL-2 activation (G) patient-derived NK cells that lysed more PC3 cells following IL-2 activation than following priming. (H–K) Alternative analysis
of data presented in (A, D, F, G) by grouping patients according to increased or decreased lysis of K562 cells following priming.
against K562 cells after priming exhibited a better cytotoxic
response to PC3 cells compared to that which was induced
following stimulation with IL-2 (Figures 2J,K). Overall,
these findings demonstrate that CTV-1 priming can enhance
cytotoxic responses of patient NK cells toward a metastatic
prostate cancer cell line, that is comparable to that of IL-
2 stimulation, and that this enhancement appears to be
irrespective of disease severity. Furthermore, these results
also demonstrate that the responsiveness to NK cell CTV-1
priming and IL-2 activation is patient-dependent, thereby
suggesting that treatment plans will need to be tailored
to the patient in order to achieve an appropriate level of
efficacy.
Correlation Between the Phenotype and
Cytotoxic Function of Resting NK Cells and
NK Cells Following CTV-1 Priming or IL-2
Activation
In parallel with the assessment of cytotoxic function, the
phenotype of the patient-derived NK cells before and after
activation was interrogated using the antibody panels described
in Tables 1, 2. In order to associate NK cell phenotype with
cytotoxic function, we performed a correlation matrix with the
percentage of resting NK cells expressing each receptor and the
percentage of K562 and PC3 lysis (Supplementary Figure 1). We
observed significant positive correlations between the percentage
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of K562 lysis and the percentage of resting NK cells expressing
NKp46 (activating receptor), CD69 (early activation marker),
CD137 and GITR (TNF receptors). Furthermore, there was
a significant positive correlation between the percentage of
NK cells expressing CD69 and both TNF receptors. Graphical
representations of a selection of these correlations are shown
in Figure 3. Although the percentage of K562 lysis correlated
with the percentage of NK cells expressing NKp46 (rs =
0.516, P = 0.0099), thereby reflecting what was observed in
our experiments with healthy volunteers (Figure 3A), the most
prominent correlation appeared to be between the percentage of
K562 lysis and the proportion of NK cells expressing CD69 (rs=
0.688, P = 0.0002) (Figures 3B). As shown in Figure 3B, NK cell
preparations that preferentially responded to IL-2 stimulation
(green), as previously measured by a greater cytotoxic response
to PC3 cells, generally exhibited a greater proportion of CD69+
NK cells compared to NK cell preparations that preferentially
responded to priming (blue).
It is plausible that thawing PBMCs up-regulated CD69 on
a greater proportion of the NK cells recovered from the IL-
2 responders and that further activation of these NK cells by
priming reduced their cytotoxic potential. Resting NK cells have
been reported not to express CD137 and to only express low levels
of GITR. However, both receptors are up-regulated following
NK cell activation (21, 22). This may account for the significant
positive correlations between CD69 expression and both CD137
and GITR expression (rs= 0.638, P= 0.0008 and rs= 0.713, P <
0.0001, respectively) reported herein (Figures 3C,D).
There was no correlation between the percentage of K562
lysis and the percentage of PC3 lysis exhibited by CTV-1 primed
NK cells (Figure 4A). However, there was a significant positive
correlation when comparing the percentage change in lysis of
K562 cells against the percentage change in lysis of PC3 cells
induced by priming (rs = 0.687, P = 0.0004) (Figure 4B). In
contrast, as shown in Figures 4C,D, only the percentage of K562
lysis and the percentage of PC3 lysis exhibited by IL-2 stimulated
NK cells were positively correlated (rs= 0.672, P= 0.008). Taken
together, it appears that CTV-1 priming and IL-2 activation
differentially regulate NK cell function. Since NK cell function
is controlled by signals delivered via activating and inhibitory
receptors expressed on the NK cell surface, it is likely that the
disparities in NK cell function are due to the differences in the
way the activation methods influence the expression of relevant
NK cell receptors.
Influence of CTV-1 Priming and IL-2
Activation on CD16, NKG2D, NKp46 and
CD69 Expression
Having observed differences in NK cell-mediated cytotoxic
responses following tumor priming and IL-2 stimulation, we next
wanted to determine whether these two approaches differentially
regulate the expression of NK cell activating receptors. Our
initial analysis on the total NK cell population revealed that
CTV-1 priming down-regulated the percentage of NK cells
expressing the activating receptors CD16, NKG2D, andNKp46 in
conjunction with an up-regulation in the percentage of NK cells
expressing CD69. These results supported the observations made
by Lowdell et al. (19, 20).
The analysis was then focussed on the CD56dim NK cell
subset which can be subdivided into three subpopulations based
on CD16 expression; CD56dimCD16high, CD56dimCD16low, and
CD56dimCD16neg. The down-regulation of CD16 expression
by CTV-1 priming altered the proportions of these three
CD56dim subpopulations. Representative density plots and gating
strategies are shown in Figures 5A,B. A decrease in the median
percentage of CD56dimCD16high NK cells (resting 72.6 vs. primed
48.7%) was observed, whereas there was an increase in the
median percentage of CD56dimCD16low NK cells (resting 17.7
vs. primed 32.7%), and CD56dimCD16neg NK cells (resting
3.2 vs. primed 11%). In comparison, the proportion of the
CD56dimCD16+/− subpopulations was not significantly altered
following stimulation with IL-2 and remained significantly
different to that of the CTV-1 primed NK cell subpopulations
(Figure 5C).
Having observed alterations in the proportions of
CD56dimCD16+/− subpopulations following NK cell priming,
the expression of NKG2D, NKp46, and CD69 on these
subpopulations was analyzed in order to determine whether
their expression differed between the three subpopulations.
As a comparison, the phenotype of IL-2 stimulated NK cells
was also determined. As shown in Figures 5D,E, compared to
resting NK cells, priming significantly decreased the proportion
of NK cells within the three CD56dimCD16+/− subpopulations
expressing NKG2D and NKp46. In contrast, only the proportion
of the CD56dimCD16neg NK cells expressing NKp46 was
decreased following IL-2 stimulation, whereas the proportion
of all three CD56dimCD16+/− subpopulations expressing
NKG2D was increased by IL-2 stimulation compared to resting
NK cells. When resting, the median proportion of the three
CD56dimCD16+/− NK cell subpopulations expressing CD69
ranged between 73.6 and 79.7% (Figure 5F). IL-2 stimulation
significantly increased the proportion of NK cells within the
three subpopulations expressing CD69 (median 94.4% to
97.1%). Interestingly, priming significantly upregulated the
expression of CD69 on only a proportion of NK cells within the
CD56dimCD16low and CD56dimCD16neg NK cell subpopulations.
The median expression for the two subpopulations was 84.9 and
89.7%, respectively (Figure 5F). Despite observing alterations
to the proportion of CD56dimCD16+/− subpopulations
expressing CD69 following activation by either method,
only the IL-2 stimulated NK cell subpopulations exhibited
a significant increase in intensity of CD69 expression
(Supplementary Figure 2).
Influence of CTV-1 Priming and IL-2
Activation on the Expression of TNF
Receptors and the CD107a Degranulation
Receptor and Their Differential Effects on
the Expression of DNAM-1 and CD96
In addition to determining the influence of CTV-1 priming on
the expression of NK cell activating receptors and co-receptors
that have previously been described by Lowdell et al. (19, 20),
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FIGURE 3 | Correlations between phenotype and cytotoxic function of resting NK cells. NK cells were isolated from thawed PBMCs that had previously been
generated from the peripheral blood of patients with benign prostate disease and patients with prostate cancer and rested over 17 h. NK cell phenotype and cytotoxic
function against K562 cells were subsequently analyzed using flow cytometry. Correlations between phenotype and function were evaluated using non-parametric
Spearman Rank correlation matrix. Graphical representations of selected significant correlations are shown; (A,B)% of K562 lysis vs. % of NK cells expressing NKp46
and CD69, respectively, (C,D) % of NK cells expressing CD69 vs. those expressing CD137 and GITR, respectively. Green dots indicate patients whose NK cells
responded better to IL-2 stimulation. Blue dots indicate patients whose NK cells responded better to being primed. Black dots indicate patients for which only priming
experiments were undertaken due to low NK cell numbers.
their influence on the expression of additional receptors was
examined. Lowdell et al. have previously shown that the priming
of NK cells using CTV-1 cells requires cell-to-cell contact (19).
We therefore decided to measure the expression of CD107a on
the surface of the primedNK cells. Since the primedNK cells used
for phenotyping came from the same pool of cells as those used
for the functional assays, we did not include monensin during the
17-h co-incubation between patient-derived NK cells and CTV-1
cells.
IL-2 stimulation and CTV-1 priming significantly increased
the proportion of all three CD56dimCD16+/− NK cell
subpopulations expressing CD107a. However, the proportion
of primed CD56dimCD16low and CD56dimCD16neg NK cell
subpopulations expressing CD107a was significantly higher than
their IL-2 stimulated counterparts (Figure 6A). A significant
increase in the median fluorescence intensity (MFI) of CD107a
expression was also only observed for primed CD56dimCD16low
and CD56dimCD16neg subpopulations. IL-2 stimulation did
not significantly increase their intensity of CD107a expression
(Supplementary Figure 3A). Interestingly, it was observed that
proportionally, CD56dimCD16neg NK cells were more able to
up-regulate the CD107a receptor, whereas the CD56dimCD16high
subpopulation were the least able to up-regulate the CD107a
receptor (Figure 6A). This was true for both primed and IL-2
stimulated NK cells.
Tumor necrosis factor (TNF) receptors such as OX40, CD137,
and GITR are up-regulated on the surface of activated NK cells.
Although well studied in T cell biology, little is known about the
role these receptors play in NK cell immunity (23). We wanted
to observe whether these receptors are up-regulated on CTV-
1 primed NK cells and play a role in the triggering of NK cell
cytotoxic responses. Resting patient-derived NK cells expressed
very little CD137 (median 1.29%, range 0.23% to 6.91%) and
OX40 (median 1.05%, range 0.11% to 5.68%) in contrast to
expression of GITR (median 26% range 3.63% to 95%). Priming
significantly increased the proportion of CD56dimCD16low
and CD56dimCD16neg subpopulations expressing the three
TNF receptors. This contrasts with IL-2 stimulation which
significantly upregulated expression of the three TNF receptors
on each CD56dimCD16+/− subset (Figures 6B–D). Similar to the
up-regulation of CD107a, the CD56dimCD16neg subpopulation
exhibited the greatest proportion of cells expressing the TNF
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FIGURE 4 | Comparing the capacity of primed and IL-2 activated NK cells to lyse K562 cells and PC3 cells. NK cells were isolated from thawed PBMCs generated
from the peripheral blood of patients with benign prostate disease and patients with prostate cancer. For each patient, the NK cells were either primed with mitomycin
C treated CTV-1 cells at a 1:2 ratio or activated with 100 IU IL-2, after which their ability to lyse K562 cells and PC3 cells at a 5:1 effector to target ratio was measured
using flow cytometry. As assessed by Spearman Rank correlations, the ability of activated NK cells (primed or IL-2 stimulated) to lyse K562 cells compared to PC3
cells are shown (A) direct comparison between % of lysed K562 cells vs. % of lysed PC3 cells by primed NK cells (B) change in lysis of K562 cells vs. change in lysis
of PC3 cells by NK cells upon priming, (C) direct comparison between % of lysed K562 cells vs. % of lysed PC3 cells by IL-2 (100 IU) activated NK cells, (D) change in
lysis of K562 cells vs. change in lysis of PC3 cells by NK cells after IL-2 activation. Green dots indicate patients whose NK cells responded better to IL-2 activation.
Blue dots indicate patients whose NK cells responded better to being primed. Black dots indicate patients for which only priming experiments were done due to low
NK cell numbers.
receptors following NK cell activation by either method. Again,
proportionally the CD56dimCD16high subpopulation was the
least able to up-regulate the TNF receptors. Furthermore, in the
context of primed NK cells, that on average exhibited the greatest
up-regulation of both CD137 and CD107a, co-expression of these
two markers on the same primed NK cell was rarely observed.
However, it should be noted that the majority of primed NK cells
did not express either marker (Supplementary Figure 4). Due to
the antibody panel design it was not possible to directly assess the
co-expression of CD107a with OX40 and GITR.
Expression of the adhesion receptors DNAM-1 and CD96
(TACTILE) was also determined. It has been proposed that
DNAM-1 is involved in the recognition stage of forming an
immunological synapse and ligates with the nectin-like protein
CD155 on the surface of the target cell (24, 25). CD96 is thought
to compete with DNAM-1, along with the inhibitory receptor
TIGIT, for ligation with CD155 (25). CTV-1 priming upregulated
DNAM-1 expression by the CD56dimCD16neg subpopulation,
both in terms of the proportion of NK cells expressing
the receptor (Figure 6E) and the intensity of expression
(Supplementary Figure 2B). Priming also significantly increased
the intensity of DNAM-1 expression on CD56dimCD16low
NK cells (Supplementary Figure 2B). In comparison, IL-2
stimulation only increased the intensity of CD96 expression on
the CD56dimCD16high and CD56dimCD16low subpopulations
(Supplementary Figure 2B). The change in expression of
CD96 following CTV-1 priming was different to that of
DNAM-1. The proportion of NK cells expressing CD96 within
all three CD56dimCD16+/− subpopulations decreased after
priming, with the intensity of CD96 expression only decreasing
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FIGURE 5 | Influence of priming and IL-2 activation on CD16 expression by CD56dim NK cells and the expression of NKG2D, NKp46, and CD69 expression by
CD56dim NK cell subpopulations expressing different levels of CD16. For each patient, isolated NK cells were either primed with mitomycin C treated CTV-1 cells at a
1:2 ratio or activated with 100 IU IL-2, after which their expression of CD16, NKG2D, NKp46, and CD69 was measured by flow cytometry and compared to that of
resting NK cells. (A,B) Strategies for the gating of live, single cell, NK subpopulations based on CD56, and CD16 expression for both resting and primed NK cells,
respectively. (C) Box and whisker plot comparing the proportion of CD56dimCD16high, CD56dimCD16low, CD56dimCD16neg populations before and after priming,
and IL-2 activation. For each CD56dim subpopulation before and after NK cell activation, box and whisker plots analyzing the proportion of NK cells expressing (D)
NKG2D, (E) NKp46, and (F) CD69. Statistical analysis was performed using two way ANOVA repeated measure tests combined with Tukey’s multiple comparisons
test and 95% confidence intervals. *< 0.05, **< 0.01, ***< 0.001, ****< 0.0001.
on the CD56dimCD16neg subpopulation (Figure 6F and
Supplementary Figure 3E). In contrast, IL-2 stimulation only
significantly upregulated the intensity of CD96 expression on the
CD56dimCD16low and CD56dimCD16neg NK cell subpopulations
(Supplementary Figure 3E).
Correlations Between Changes in NK Cell
Phenotype and Changes in Cytotoxic
Function Following CTV-1 Priming and IL-2
Activation
Lowdell et al. have proposed that the NK cell cytotoxic
mechanism can be split into two stages; priming and triggering
(16, 19). It was suggested that the CD69 receptor acts
as a triggering receptor, but that more triggering receptors
exist (19). In an attempt to assign potential “priming” and
“triggering” attributes to the NK cell receptors that were
measured in this study, for each patient we calculated (1)
the change in expression of all receptors measured and (2)
the change in lysis of K562 and PC3 cells, following NK
cell activation and performed a series of non-parametric
correlation matrices using data on receptor expression on
total NK cells (Supplementary Figure 5) and data on receptor
expression by the three CD56dimCD16+/− subpopulations
(Supplementary Figure 6). Key significant correlations from
these matrices were selected and XY scatter plots created in
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FIGURE 6 | Influence of priming and IL-2 activation on the phenotype of CD56dim NK cell subpopulations. For each patient, isolated NK cells were either primed with
mitomycin C treated CTV-1 cells at a 1:2 ratio or activated with 100 IU IL-2, after which the expression of CD107a, CD137, OX40, GITR, DNAM-1, and CD96 by
CD56dimCD16high, CD56dimCD16low, CD56dimCD16neg NK subpopulations was measured by flow cytometry and compared to that of resting NK cells. Box and
whisker plots show the proportion of each NK cell subpopulation expressing (A) CD107a, (B) CD137, (C) OX40, (D) GITR, (E) DNAM-1, (F) CD96. Statistical analysis
was performed using two way ANOVA repeated measure tests combined with Tukey’s multiple comparisons test and 95% confidence intervals. *< 0.05, **< 0.01,
***< 0.001, ****< 0.0001.
order to better observe and interpret these correlations from a
biological point of view. We color coded the points to identify
patients who preferentially responded to IL-2 stimulation for
the lysis of PC3 cells (green) and patients who preferentially
responded to CTV-1 priming (blue). Data from patients from
whom too few NK cells were recovered to perform both the
priming and IL-2 stimulation experiments are colored black.
Only the expression of the activating receptors NKp46
and DNAM-1 correlated with the lysis of K562 and PC3
cells (Figure 7). A decrease in the proportion of NK cells
expressing NKp46, as result of CTV-1 priming, positively
correlated with a decrease in the ability of the NK cells
to kill both K562 cells (rs = 0.487, P = 0.0252) and
PC3 cells (rs = 0.457, P = 0.0372) (Figures 7A,B). Despite
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all three CD56dimCD16+/− subpopulations down-regulating
NKp46 (Figure 5E) following NK cell priming, only changes in
the phenotype of the CD56dimCD16low and CD56dimCD16neg
populations significantly correlated with the decrease in lysis
of both target cells (Figures 7C–F). The data revealed a trend
that those patients whose NK cells preferentially responded to
IL-2 stimulation, thereby enhancing their ability to lyse PC3
cells, tended to down-regulate more NKp46 than the NK cells
from patients that preferentially responded to tumor priming
(Figures 7D,F). Changes in the proportion of NK cells expressing
DNAM-1 in the three CD56dimCD16+/− subpopulations as a
result of priming were small (<6%) (Figures 7G,H). An increase
in the proportion of CD56dimCD16low NK cells expressing
DNAM-1 positively correlated with the lysis of K562 (rs =
0.567, P = 0.0073). In contrast, a decrease in the proportion
of CD56dimCD16high NK cells expressing DNAM-1 negatively
correlated with an increase in the lysis of PC3 cells (rs = 0.661,
P = 0.0011).
In contrast to primed NK cells, lysis of K562 and PC3 cells
by IL-2 stimulated NK cells did not correlate with the change
in expression of any activating receptors (Figure 8). Instead, the
lysis of K562 cells only positively correlated with an increased
proportion of CD69 positive cells (rs = 0.558, P = 0.0085)
(Figure 8A). However, this increase in the proportion of CD69
positive cells negatively correlated with the ability of the IL-
2 stimulated NK cells to lyse PC3 cells (rs = −0.506, P =
0.0193) (Figure 8B). Interestingly, an increase in the proportion
of NK cells up-regulating the TNF receptors CD137 and OX40
following stimulation with IL-2 positively correlated with an
increase in the ability of the NK cells to kill PC3 cells (rs =
0.484, P = 0.0261 and rs = 0.461, P = 0.0353, respectively)
(Figures 8C,D).
NKG2D has been commonly reported to be an important
activating receptor for the recognition and killing of cancer
cells, including prostate cancer (26–29). However, changes in
the proportion of NK cells expressing NKG2D after NK cell
priming did not correlate with the ability of the primed NK
cells to lyse K562 and PC3 cells in the current study. Instead,
proportionally, NKG2D expression positively and significantly
correlated with the expression of CD96 and the three TNF
receptors (Figures 9A–D). The results showed that a priming-
induced reduction in the proportion of NK cells expressing
NKG2D was associated with a reduction in the proportion
of NK cells expressing CD96 (rs = 0.459, P = 0.0362)
(Figure 9A). As previously shown in Figures 6B–D, priming up-
regulated CD137, OX40, and GITR expression. The correlations
in Figures 9B–D show that the up-regulation of these TNF
receptors on primed NK cells was associated with retaining
NKG2D on the surface of primed NK cells. The greater the
proportion of primed NK cells down-regulating NKG2D, then
the smaller the proportion of NK cells up-regulating CD137 (rs=
0.466, P = 0.0331), OX40 (rs= 0.529, P = 0.0136), and GITR (rs
= 0.529, P = 0.0136). Interestingly the expression of CD69 also
correlates with the expression of CD96 and the expression of the
three TNF receptors. The greater the proportion of primed NK
cells down-regulating CD96 expression the lower the proportion
of primed NK cells up-regulating CD69 expression (rs= 0.551, P
= 0.0097) (Figure 9E). In general, an increased proportion of NK
cells up-regulating CD69 expression upon CTV-1 priming was
associated with an increased proportion of NK cells expressing
CD137 (rs = 0.662, P = 0.0011), OX40 (rs = 0.603, P = 0.0038),
and GITR (rs = 0.902, P < 0.0001) (Figures 9F–H). However,
it was noted that an up-regulation in the expression of all three
receptors also occurred in the absence of an up-regulation in
the expression of CD69. Considering that the up-regulation of
the three TNF receptors on NK cells correlates with CTV-1
priming and the expression of CD69, it was not surprising that
expression of the three TNF receptors positively, and significantly
correlated with each other (Figures 10A–C). However, only the
expression of GITR positively correlated with the expression of
CD96 (Figure 10D). In general, the greater the proportion of NK
cells down-regulating CD96, then the lower the proportion of NK
cells up-regulating GITR (rs= 0.455, P = 0.0384).
Although priming resulted in a positive correlation between
CD69 expression and TNF receptor expression, IL-2 stimulation
resulted in a negative correlation between the expression of CD69
and that of the TNF receptors CD137 and OX40. As shown
in Figures 10E,F, respectively, an increase in the proportion
of NK cells up-regulating CD69 negatively correlated with the
proportion of NK cells up-regulating CD137 (rs = −0.710, P <
0.0001) and OX40 (rs = −0.565, P = 0.0076). Interestingly, NK
cells from those patients that already included a high proportion
of NK cells expressing CD69 prior to IL-2 stimulation appeared
more likely to up-regulate CD137 and OX40. Similarly to primed
NK cells, a highly significant positive correlation between the
up-regulation of OX40 and CD137 by IL-2 stimulated NK cells
was observed (rs = 0.741, P = 0.0001) (Figure 10G). In contrast
to primed NK cells, no significant correlation was observed
between the proportion of IL-2 stimulated NK cells expressing
GITR and those expressing CD69. However, the proportion of
IL-2 stimulated NK cells up-regulating NKG2D did positively
correlate with the proportion of NK cells up-regulating GITR (rs
= 0.603, P = 0.0038) (Figure 10H). Overall, it appears that NK
cell priming and IL-2 activation differentially regulate CD137,
OX40, and GITR expression.
DISCUSSION
NK cells have immunotherapeutic potential for the treatment
of cancer due to their natural ability to kill cancerous cells
and a number of NK cell-based immunotherapies are now in
development (10–15).
One approach has previously been proposed by Lowdell et al.
who discovered that CTV-1 cells (ALL cell line) could “prime”
NK cells from healthy volunteers and enhance their ability to kill
NK cell-resistant cancer cell lines such as the DU145 metastatic
prostate cancer cell line (19, 20). Furthermore, Lowdell et al.
also noted that NK cells undergo alterations in phenotype upon
priming (19, 20). Most notably, primed NK cells down-regulated
their expression of activating receptors NKG2D, NKp46, and
NKp80 and this was associated with enhanced cytotoxic function
(20). This is in contrast to the down-regulation of NK cell
activating receptors and resulting inhibition of NK cell cytotoxic
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FIGURE 7 | Correlation between changes in expression of NKp46 and DNAM-1 by patient-derived NK cells following priming with changes in their ability to lyse K562
and PC3 cells. Using phenotypic profiles from patients with prostate cancer, a Spearman Rank correlation matrix was performed to identify correlations between the
changes in NK cell phenotype and cytotoxic potential after priming at a 1:2 NK:CTV-1 ratio. Correlation between changes in the proportion of NK cells expressing
NKp46 and target cell lysis; (A,B) killing of K562 and PC3 cells by the total NK cell population, (C,D) killing of K562 and PC3 cells by the CD56dimCD16low NK cells,
(E,F) killing of K562 and PC3 cells by CD56dimCD16neg NK cells. Correlation between changes in the proportion of CD56dimCD16low NK cells expressing DNAM-1
(Continued)
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FIGURE 7 | and change in the lysis of K562 cells (G). Correlation between changes in the proportion of CD56dimCD16high NK cells expressing DNAM-1 and change
in lysis of PC3 cells (H). Green dots indicate patients whose NK cells responded better to IL-2 activation. Blue dots indicate patients whose NK cells responded better
to being primed. Black dots indicate patients for which only priming experiments were done due to low NK cell numbers.
FIGURE 8 | Correlation between changes in CD69, CD137, and OX40 expression by patient-derived NK cells after activation with IL-2 and changes in their ability to
lyse K562 and PC3 cells. Using phenotypic profiles from patients with prostate cancer, a Spearman Rank correlation matrix was performed to identify correlations
between the changes in NK cell phenotype and cytotoxic potential after activation with 100 IU IL-2. Correlation between change in % of patient NK cells expressing
CD69 following IL-2 stimulation and changes in the % of K562 cell lysis (A) and % of PC3 lysis (B). (C,D) Correlation between changes in the % of patient NK cells
expressing CD137 and OX40 and changes in the % of PC3 cell lysis after IL-2 stimulation. Green dots indicate patients whose NK cells responded better to IL-2
activation. Blue dots indicate patients whose NK cells responded better to being primed.
functions which is generally associated with exposure of NK
cells to immunosuppressive cytokines (e.g., TGF-β) produced by
tumors and suppressive immune cell populations (e.g., Tumor
AssociatedMacrophages, TAMs) (16, 20, 30). Therefore, not only
is the priming of NK cells using CTV-1 cells a method of NK
cell activation with potential immunotherapeutic application,
it may also serve as a model that can be used to improve
our understanding of the mechanisms involved in NK cell
cytotoxicity. Although the application of CTV-1 primed NK cells
in a clinical setting has to date been limited, the adoptive transfer
of CTV-1 primed NK cells into humans has shown that primed
NK cells can promote durable complete remission in some high
risk patients with acute myeloid leukaemia (AML) who were not
candidates for hematopoietic cell transplantation (31).
The aim of this study was to compare and contrast the
influence of CTV-1 priming and IL-2 activation of NK cells, an
approach which has been shown to have immunotherapeutic
potential in a number of settings (14, 15), from patients
with prostate cancer on their ability to kill the NK cell-
resistant cell line PC3 which is considered to represent an
aggressive form of metastatic prostate cancer (32). We also
wanted to understand how changes in the phenotype of
primed and IL-2 activated NK cells influence their cytotoxic
function.
Irrespective of disease status (i.e., benign, low grade cancer
or high grade cancer) our data showed that patient-derived
NK cells respond to being primed with CTV-1 cells and that
this triggered an increase in their ability to lyse PC3 prostate
cancer cells (up to 37%). This increased ability to lyse PC3 cells
was comparable to that of IL-2 stimulation. Importantly, the
capacity of priming and IL-2 stimulation to trigger cytotoxicity
was patient-dependent, in that NK cells from ∼50% of patients
preferentially responded to CTV-1 priming whereas NK cells
from the remaining patients preferentially responded to IL-
2 stimulation. Such patient-specific responsiveness has been
observed in other immunotherapeutic settings such as the use
of checkpoint inhibitors (33, 34) and reiterates the need for the
development of “companion diagnostics” that can identify those
patients that will benefit from a defined immunotherapy (35).
In general, CTV-1 priming and IL-2 stimulation enhanced
NK cell cytotoxicity against PC3 cells. However, although IL-2
stimulation always enhanced K562 lysis, priming did not. K562
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FIGURE 9 | Correlations between changes in NKG2D and CD69 expression by patient-derived NK cells after priming with changes in TNF receptor and CD96
expression. Using phenotypic profiles from patients with prostate cancer, changes in the proportion of NK cells expressing each receptor after priming at a 1:2
NK:CTV-1 ratio were calculated. Using these calculations, a Spearman Rank correlation matrix was performed to identify correlations between the expression of NK
cell receptors. Graphical representations of significant correlations between receptors expressed by primed NK cells are shown; (A) NKG2D vs. CD96, (B) NKG2D vs.
CD137, (C) NKG2D vs. OX40, (D) NKG2D vs. GITR, (E) CD69 vs. CD96, (F) CD69 vs. CD137, (G) CD69 vs. OX40, (H) CD69 vs. GITR. Green dots indicate patients
whose NK cells responded better to IL-2 activation. Blue dots indicate patients whose NK cells responded better to being primed. Black dots indicate patients for
which only priming experiments were done due to low NK cell numbers.
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FIGURE 10 | Correlations between expression of TNF receptors, NKG2D, CD69, and CD96 by patient-derived NK cells after priming or IL-2 activation. Using
phenotypic profiles from patients with prostate cancer, changes in the proportion of NK cells expressing each receptor after priming or activation with 100 U/ml IL-2
were calculated. Using these calculations, Spearman Rank correlation matrices for primed NK cells and IL-2 stimulated NK cells were used to identify correlations in
expression of NK cell receptors. Graphical representations of significant correlations between pairs of receptors expressed by primed NK cells are shown; (A) CD137
vs. GITR, (B) GITR vs. OX40, (C) CD137 vs, OX40, (D) GITR vs. CD96. Graphical representations of significant correlations between pairs of receptors expressed
(Continued)
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FIGURE 10 | by IL-2 stimulated NK cells are shown; (E) CD69 vs. CD137, (F) CD69 vs. OX40, (G) CD137 vs. OX40, (H) NKG2D vs. GITR. Green dots indicate
patients whose NK cells responded better to IL-2 activation. Blue dots indicate patients whose NK cells responded better to being primed. Black dots indicate
patients for which only priming experiments were done due to low NK cell numbers.
cells areMHC class I negative cells and are thus highly susceptible
to lysis by NK cells as they do not provide MHC class I-triggered
inhibitory signals to the NK cell. Yet despite this, NK cells from
only 7 of the 22 patients in our study were able to lyse>56% of the
K562 cells within the timeframe of the cytotoxicity assay, whereas
NK cells from the remaining patients lysed <24%. Although
it might be assumed that NK cells from these patients were
exhibiting a degree of cytotoxic dysfunction, our data suggest that
this is not the case, as the NK cells from these patients responded
better to being primed by CTV-1 cells, thereby enabling them to
increase their lysis of PC3 cells to greater extent than when they
were stimulated with IL-2. In contrast, NK cells from the seven
patients that exhibited a high level of K562 lysis at rest responded
poorly to being primed with CTV-1 cells.
Overall our data questions current understanding of NK cell
dysfunction. It appears that NK function is determined by (1)
the composition and phenotypes of the NK cell populations at
rest, (2) the type of stimulus used to activate the NK cell (i.e.,
cytokine or a combination of membrane bound ligands), and
(3) the effect this stimulus has on the NK cell phenotype which
then determines their ability to lyse subsequent targets. Our data
suggest that NK cells need the correct stimulation to achieve a
functional response and a failure to respond to one target (or
stimulus) does not necessarily indicate a failure to respond to
another.
Our observations support the notion that theNK cell cytotoxic
mechanism can indeed be divided into the two stages; “priming”
and “triggering,” first postulated by Lowdell et al. (16, 19). Our
data suggest that only a proportion of the NK cells can respond
to an activation stimulus and this is likely due to the vast number
of different NK cell subpopulations that exist in one individual,
with each subpopulation expressing a different combination of
receptors, as has been reported by Horowitz et al. (36). Although
the NK cell activating and inhibitory receptor repertoire appears
to be large, NK cells do not appear to express all the receptors
at the same time. Therefore, when NK cells are stimulated with
a cytokine (e.g., IL-2) or come into contact with a target cell
expressing a specific combination of ligands, only a proportion of
the NK cells are capable of responding. IL-2 stimulation had no
effect on the expression of CD16, but did increase the proportion
of NK cells expressing NKG2D, CD69, CD107a, CD137, OX40,
GITR, and also the intensity of CD96 expression. However, it
should be noted that the correlation between the expression
of CD69 and the two TNF receptors CD137 and OX40 was
negative, which is in contrast to the positive correlation exhibited
by primed NK cells. In the case of priming, down-regulation
of CD16 appeared to be an important indicator of response to
stimulus, although not exclusively as a small proportion of the
CD56dimCD16high population upregulated CD107a expression
which is indicative of degranulation. Similar to interactions
between NK cells and K562 cells, cell-to-cell contact between NK
cells and CTV-1 cells has been reported to down-regulate or lead
to the shedding of CD16 (19, 37–39). We found that the shedding
of CD16 on a proportion of NK cells following priming with
CTV-1 cells decreases the proportion of CD56dimCD16high NK
cells in the NK cell population which coincided with an increase
in the proportion of CD56dimCD16low or CD56dimCD16neg
NK cells. This observation is analogous to that observed by
Jewett et al. who observed that loss of CD16 expression by
NK cells following exposure to K562 cells was only observed
on those NK cells that could form conjugates with the NK
cells (37). In our study, analysis of the three CD56dimCD16+/−
subpopulations following priming with CTV-1 cells revealed a
link between the extent of CD16 shedding and the up-regulation
of the activation marker CD69 similar to that observed by Jewett
et al. (37). Additionally, we observed the up-regulation of three
TNF receptors (CD137, OX40, GITR) and the up-regulation of
the degranulation receptor CD107a. Compared to resting NK
cells, both CD56dimCD16low NK cells and CD56dimCD16neg NK
cells significantly upregulated all five receptors. Proportionally,
a greater percentage of NK cells within the CD56dimCD16neg
subpopulation expressed the CD107a and TNF receptors
compared to the CD56dimCD16low subpopulation. In contrast,
the CD56dimCD16high subpopulation only significantly up-
regulated CD107a. The extent of TNF receptor up-regulation
on primed NK cells positively correlated with the up-
regulation of CD69, which itself correlated positively with the
expression of CD96. Interestingly, only the CD56dimCD16low
and CD56dimCD16neg subpopulations significantly up-regulated
CD69 expression, therefore explaining the absence of TNF
receptor up-regulation on the CD56dimCD16high subpopulation.
To put our observations into context with the literature, our
data suggest that successful priming of NK cells by tumor cells
involves the ligation of multiple NK cell activating receptors,
two of which appear to be NKG2D and CD96. Interestingly the
expression of NKG2D and CD96 positively correlates with each
other, with the down-regulation of one being associated with
the down-regulation of the other. Retention of CD96 expression
at the NK cell surface is important for NK cell activation,
as measured by CD69 expression. The retention of NKG2D
and the up-regulation of CD69 at the cell surface of primed
NK cells appears to be important for the up-regulation of the
TNF receptors. It is unclear whether the down-regulation of
the activating receptors that occurs with priming to a degree
is the result of ligation with ligands expressed on the CTV-1
cell surface or due to exposure of immunosuppressive cytokines
secreted by CTV-1 cells, despite them having been treated with
mitomycin C. The data suggest that both NKG2D and CD96
are required for priming NK cells, but not for the triggering
of cytotoxic granule release. In contrast, the activating receptor
NKp46 showed no association with NK cell activation, but did
appear to correlate with target cell lysis of both K562 and PC3
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cells, thereby suggesting a role in the triggering of cytotoxic
responses. Strangely, CD107a did not positively correlate with
K562 and PC3 lysis. This may be due to the fact that we did
not use monensin to retain CD107a expression on the surface
of the primed NK cells, which is common practice in indirect
cytotoxic killing assays (40). Although monensin was not used,
we still observed CD107a expression on the surface of NK cells
17 h post co-incubation with CTV-1 cells, thereby suggesting that
NK cells continue to kill CTV-1 cells over this length of time.
Interestingly, following contact with CTV-1 cells over this 17 h
period, which for some primed NK cells resulted in a cytotoxic
response, the same primed NK cells could lyse a metastatic
prostate cancer cell line which is typically resistant to lysis by
resting NK cells. At this point we do not know whether it is
the same primed NK cells lysing both CTV-1 and PC3 cells. A
study by Jewett et al. revealed that NK cells dissociated from
MHC class I deficient K562 cells following initial conjugation
display anergy resulting in decreased cytotoxic function due to a
reduced ability to form conjugates (37). Subsequent work by this
group revealed that the NK cells that formed conjugates could be
further subdivided into “binders” and “killers”. The “binders” and
“killers” displayed “split anergy” with “binder” NK cells forming
conjugates for a longer period of time compared to “killers.” As
a result, “binders” suffered from target induced inactivation and
induction of apoptosis (39). Although we did not specifically
set out to measure conjugation between NK cells and CTV-1
cells, we did observe a reduction in the number of viable NK
cells as a result of priming (data not shown) which suggests that
conjugates between NK cells and CTV-1 cells may also promote
a split anergy. However, in contrast to K562 cells, CTV-1 cells
enhance the ability of NK cells to kill PC3 cells, suggesting that
CTV-1 (MHC class I positive) cells do not impair the ability
of primed NK cells to form conjugates with subsequent target
cells.
Enhanced cytotoxic function by NK cells following initial
exposure to acute lymphoblastic leukemia cells has been observed
in other studies. A study by Pal et al. revealed that upon primary
exposure to acute B cell precursor leukemic cell lines, healthy NK
cells acquired a mode of functional memory enabling them to
enhance their cytotoxic capacity against the same cell line upon
secondary exposure (41). However, in contrast to the CD56dim-
based phenotype of the CTV-1 primed NK cells described in this
study, the tumor induced memory-like NK cells described by Pal
et al. were instead associated with the CD56bright subpopulation.
NK cells appear to be relatively “plastic” and their immune
response depends on the extent and type of external stimuli they
receive.
To fully realize the immunotherapeutic potential of CTV-1
primed NK cells, further characterization of their phenotype,
function, and the mechanisms involved in their generation
is required (42). Current immunotherapeutic strategies have
shown little or no efficacy for the treatment of prostate cancer
and therefore new alternative strategies need to be explored
(9, 43). This study supports a role for stratified NK cell-
based therapeutics in the prostate cancer setting and warrants
further investigation. However, it should be noted that one
limitation of this study was the use of only one allogenic
metastatic prostate cancer cell line (i.e., PC3 cells) as a target
for primed and IL-2 activated NK cells in vitro and an
inability to undertake profiling of cytokine responses following
priming and activation due to limited sample availability. Further
assessment of cytotoxic responses against multiple metastatic
prostate cancer cell lines and/or primary prostate cancer cell
lines are needed and, ideally, these would be combined with an
assessment of “triggering” receptor ligand interactions in order
to further interrogate the efficacy of using CTV-1 primed and
IL-2 activated NK cell populations for the treatment of prostate
cancer.
Our study also highlights an area for further investigation
which concerns the role of TNF receptors in NK cell biology.
A limitation of the current study is that the analysis was
limited to the co-expression of CD137 and CD107a. The data
suggested that these two receptors are rarely co-expressed and
therefore CD137 does not appear to be associated with the
triggering of NK cell cytotoxic responses. However, since we
did not use monensin in our experiments to retain CD107a
expression at the cell surface, we cannot completely rule out this
possibility. TNF receptors act as co-stimulatory receptors that
provide bidirectional signaling between effector cells and their
targets (23). Currently, the majority of information regarding
TNF receptors has been derived from T cell studies, although
information regarding their function in the setting of NK cells
is beginning to emerge. It has been shown that ligation of
OX40 with OX40L expressed on activated T cells and activated
monocytes promotes NK cell proliferation (44, 45). Ligation of
GITR with GITRL secreted by tumor cells or with agonistic
anti-GITR antibodies results in down-regulation of NK cell
cytotoxic responses, proliferation and IFN-γ production, while
promoting NK cell apoptosis (21, 46). Ligation of CD137
with CD137L expressed on AML cells from patients also
reduced NK cell cytotoxicity and IFN-γ production. Blocking
CD137 and CD137L interactions restored NK cell cytotoxicity,
but not IFN-γ production (22). In our study, co-incubation
of NK cells with CTV-1 cells induced the expression of
all three TNF receptors, thus representing an opportunity
not only to investigate these receptors, but also to further
manipulate the primed NK cell response in a therapeutic setting
using monoclonal antibodies that target these receptors. Such
antibodies are currently in development or/and undergoing
clinical trials (47, 48).
In summary, this study presents a comprehensive,
comparative analysis of changes in NK cell phenotype and
function following priming by CTV-1 cells and activation by
IL-2 and new insights into the correlation between changes in
phenotype and function. Although the findings demonstrate
that the priming and activation of NK cells has potential as
an immunotherapy for the treatment of prostate cancer, it
also shows that not all patients will benefit from a particular
therapeutic approach. Our interrogation of the consequences
of priming and activation on NK cell biology provides an
opportunity to predict and optimize therapeutic potential.
Our findings also confirm that the targeting of TNF receptors
and other pathways using monoclonal antibodies may further
enhance the cytotoxic potential of NK cells by blocking
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NK cell-directed inhibitory signals, as has been discussed
previously (15).
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